Keratoacanthoma
☆ AI Dermatology — Free Service
I 2022 Stiftung Warentest-resultaterne fra Tyskland var forbrugernes tilfredshed med ModelDerm kun lidt lavere end med betalte telemedicinske konsultationer.
I 2022 Stiftung Warentest-resultaterne fra Tyskland var forbrugernes tilfredshed med ModelDerm kun lidt lavere end med betalte telemedicinske konsultationer.
Typisk keratoacanthoma
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) er en hyppigt forekommende hudtumor, kendt for sin hurtige vækst og sit potentiale til at regressere af sig selv. Den forekommer typisk hos ældre, lyshudede mænd med en historie med solskader. Mens kirurgisk fjernelse ved hjælp af excision eller Mohs mikrografisk kirurgi er den sædvanlige behandling, findes der flere andre terapimuligheder.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) er en lavgradig tumor, der opstår i visse hudkirtler og ligner en squamous cell carcinoma (SCC) under mikroskopet. Der er løbende debat om, hvorvidt KA skal klassificeres som en form for invasiv SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) er den næsthyppigste kræftform hos mennesker, især blandt ældre personer. Kirurgi er den primære behandling af cSCC, men for patienter, der ikke kan opereres eller vælger at undgå operation, kan andre muligheder såsom intralæsionelle behandlinger overvejes. Traditionelle intralæsionelle behandlinger (methotrexate eller 5-fluorouracil) er blevet anvendt, men der pågår løbende forskning i nye tilgange såsom intralæsional immunterapi og onkolytisk viroterapi. Her vil vi gennemgå forskellige intralæsionelle behandlinger for cSCC, fra klassiske metoder til banebrydende strategier.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Under mikroskopet ligner keratoacanthoma meget pladecellekarcinom. Mens nogle patologer klassificerer keratoacanthoma som en særskilt enhed og ikke som en malignitet, udvikler omkring 6 % af de kliniske og histologiske keratoacanthomaer sig til invasiv og aggressiv pladecellekræft.
○ Diagnose og behandling
#Dermoscopy
#Skin biopsy